OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

This study is for individuals aged between 5 and 30 years old who have Prader-Willi Syndrome. To be considered, you must have already successfully completed a previous study involving carbetocin (Study ACP-101-302) and met all the entry rules for that initial study. Your doctor would also need to believe that you would benefit from continuing to receive the carbetocin treatment for a longer time.

You would also need to live with a caregiver who is willing and able to understand and follow all the study procedures and attend all scheduled appointments. This is important to ensure the study runs smoothly and safely for everyone involved.

There are certain health conditions that would prevent someone from joining, such as a history of stroke, serious brain injury, epilepsy, or frequent severe migraines. If you have active severe mental health symptoms, or a history of significant mental health issues like psychosis or suicide attempts, you would not be able to participate. Also, if you have certain heart conditions or have had problems tolerating the study medication or procedures in the previous study, you might not be suitable.

If you join this study, you will continue to use the carbetocin nasal spray three times a day. You and your caregiver will need to attend regular appointments at the study clinic. These visits will involve health checks, such as measuring your vital signs (like blood pressure and heart rate), and ECGs (heart rhythm tests) to monitor how your heart is doing. The study team will also be asking about any side effects you might experience and how well you are managing with the nasal spray. The exact total duration of your participation will depend on the study design, but it is an open-label extension, meaning it's designed for long-term follow-up for those who completed the initial study.